Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
2 "Chang Su"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Pharmacotherapy
Article image
Novel Insights into the Causal Relationship between Antidiabetic Drugs and Adverse Perinatal Outcomes: A Mendelian Randomization Study
Chang Su, Xueqing He, Xiaona Chang, Juan Tian, Guang Wang, Jia Liu
Diabetes Metab J. 2025;49(6):1242-1251.   Published online June 2, 2025
DOI: https://doi.org/10.4093/dmj.2024.0521
  • 4,572 View
  • 188 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Hyperglycemia during pregnancy increases the risk of adverse perinatal outcomes and birth defects. Evidence regarding the long-term safety of antidiabetic drugs during pregnancy is still lacking.
Methods
A two-sample Mendelian randomization (MR) study was performed to assess the causal association between six antidiabetic drug targets (ABCC8, DPP4, INSR, GLP1R, PPARG, and SLC5A2) and seven adverse perinatal outcomes and five congenital malformation outcomes. Inverse variance weighted (IVW) was adopted as the main MR method, and sensitivity analysis using traditional MR methods was performed to evaluate the robustness of the results.
Results
We observed strong evidence that sodium-glucose cotransporter 2 (SGLT2) inhibitors (odds ratio [OR], 0.084; 95% confidence interval [CI], 0.009 to 0.834; P=0.034) reduces the risk of preterm birth; genetic variation in sulfonylurea drug targets (OR, 0.015; 95% CI, 2.50E-04 to 0.919; P=0.045) and genetic variation in thiazolidinedione drug targets (OR, 0.007; 95% CI, 4.16E-04 to 0.121; P=0.001) reduced the risk of eclampsia/preeclampsia; glucagon-like peptide 1 (GLP-1) analogues target (β=–0.549; 95% CI, –0.958 to –0.140; P=0.009) was inversely associated with fetal birth weight; thiazolidinedione target was inversely associated with gestational age (β=–0.952; 95% CI, –1.785 to –0.118; P=0.025); SGLT2 inhibitors reduced the risk of cardiocirculatory malformations (OR, 0.001; 95% CI, 8.75E-06 to 0.126; P=0.005).
Conclusion
Most antidiabetic drugs are safe when used during the perinatal period. Of note, GLP-1 analogues may lead to a risk of low birth weight, while thiazolidinediones may lead to a reduction in fetal gestational age.

Citations

Citations to this article as recorded by  
  • Prenatal chemical exposures and fetal growth: a narrative review of gene-environment interactions (2025)
    Sumitaka Kobayashi, Fumihiro Sata, Yasuaki Saijo, Reiko Kishi
    Pediatric Research.2026;[Epub]     CrossRef
A study on erythrocyte deformability in diabetes mellitus.
In Saeng Lee, Kyoung Saeng Lee, Su Yong Han, Jung Keun Kim, Seong Bum Jin, Young Woo Lee, Chang Sup Song
Korean Diabetes J. 1993;17(1):79-87.   Published online January 1, 2001
  • 1,281 View
  • 19 Download
AbstractAbstract PDF
No abstract available.

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP